Outcomes with the use of recombinant human erythropoietin in critically ill burn patients

Jonathan B. Lundy, Katherine Hetz, Kevin K. Chung, Evan M. Renz, Christopher E. White, Booker T. King, Todd Huzar, Steven Wolf, Lorne H. Blackbourne

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Recent data demonstrate a possible mortality benefit in traumatically injured patients when given subcutaneous recombinant human erythropoietin (rhEPO). The purpose of this report is to examine the effect of rhEPO on mortality and transfusion in burn patients.We conducted a review of burn patients (greater than 30% total body surface area, intensive care unit [ICU] days greater than 15) treated with 40,000u rhEPO over an 18-month period (January 2007 to July 2008). Matched historical controls were identified and a contemporaneous cohort of subjects not administered rhEPO was used for comparison (NrhEPO). Mortality, transfusions, ICU and hospital length of stay were assessed. A total of 105 patients were treated (25 rhEPO, 53 historical control group, 27 NrhEPO). Hospital transfusions (mean 13,704 ± mL vs 13,308 ± mL; P 5 0.42) and mortality (29.6 vs 32.0%; P = 0.64) were similar. NrhEPO required more blood transfusions (13,308 ± mL vs 6,827 ± mL; P = 0.004). No difference in mortality for the rhEPO and NrhEPO (32.0 vs 22.2%; P = 0.43) was found. Thromboembolic complications were similar in all three groups. No effect was seen for rhEPO treatment on mortality or blood transfusion requirements in the severely burned.

Original languageEnglish (US)
Pages (from-to)951-956
Number of pages6
JournalAmerican Surgeon
Volume76
Issue number9
StatePublished - Sep 1 2010
Externally publishedYes

Fingerprint

Erythropoietin
Critical Illness
Mortality
Blood Transfusion
Intensive Care Units
Length of Stay
Body Surface Area
Control Groups

ASJC Scopus subject areas

  • Surgery

Cite this

Lundy, J. B., Hetz, K., Chung, K. K., Renz, E. M., White, C. E., King, B. T., ... Blackbourne, L. H. (2010). Outcomes with the use of recombinant human erythropoietin in critically ill burn patients. American Surgeon, 76(9), 951-956.

Outcomes with the use of recombinant human erythropoietin in critically ill burn patients. / Lundy, Jonathan B.; Hetz, Katherine; Chung, Kevin K.; Renz, Evan M.; White, Christopher E.; King, Booker T.; Huzar, Todd; Wolf, Steven; Blackbourne, Lorne H.

In: American Surgeon, Vol. 76, No. 9, 01.09.2010, p. 951-956.

Research output: Contribution to journalArticle

Lundy, JB, Hetz, K, Chung, KK, Renz, EM, White, CE, King, BT, Huzar, T, Wolf, S & Blackbourne, LH 2010, 'Outcomes with the use of recombinant human erythropoietin in critically ill burn patients', American Surgeon, vol. 76, no. 9, pp. 951-956.
Lundy JB, Hetz K, Chung KK, Renz EM, White CE, King BT et al. Outcomes with the use of recombinant human erythropoietin in critically ill burn patients. American Surgeon. 2010 Sep 1;76(9):951-956.
Lundy, Jonathan B. ; Hetz, Katherine ; Chung, Kevin K. ; Renz, Evan M. ; White, Christopher E. ; King, Booker T. ; Huzar, Todd ; Wolf, Steven ; Blackbourne, Lorne H. / Outcomes with the use of recombinant human erythropoietin in critically ill burn patients. In: American Surgeon. 2010 ; Vol. 76, No. 9. pp. 951-956.
@article{2c78bf46202146d3ba47d7269858ba72,
title = "Outcomes with the use of recombinant human erythropoietin in critically ill burn patients",
abstract = "Recent data demonstrate a possible mortality benefit in traumatically injured patients when given subcutaneous recombinant human erythropoietin (rhEPO). The purpose of this report is to examine the effect of rhEPO on mortality and transfusion in burn patients.We conducted a review of burn patients (greater than 30{\%} total body surface area, intensive care unit [ICU] days greater than 15) treated with 40,000u rhEPO over an 18-month period (January 2007 to July 2008). Matched historical controls were identified and a contemporaneous cohort of subjects not administered rhEPO was used for comparison (NrhEPO). Mortality, transfusions, ICU and hospital length of stay were assessed. A total of 105 patients were treated (25 rhEPO, 53 historical control group, 27 NrhEPO). Hospital transfusions (mean 13,704 ± mL vs 13,308 ± mL; P 5 0.42) and mortality (29.6 vs 32.0{\%}; P = 0.64) were similar. NrhEPO required more blood transfusions (13,308 ± mL vs 6,827 ± mL; P = 0.004). No difference in mortality for the rhEPO and NrhEPO (32.0 vs 22.2{\%}; P = 0.43) was found. Thromboembolic complications were similar in all three groups. No effect was seen for rhEPO treatment on mortality or blood transfusion requirements in the severely burned.",
author = "Lundy, {Jonathan B.} and Katherine Hetz and Chung, {Kevin K.} and Renz, {Evan M.} and White, {Christopher E.} and King, {Booker T.} and Todd Huzar and Steven Wolf and Blackbourne, {Lorne H.}",
year = "2010",
month = "9",
day = "1",
language = "English (US)",
volume = "76",
pages = "951--956",
journal = "The American surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "9",

}

TY - JOUR

T1 - Outcomes with the use of recombinant human erythropoietin in critically ill burn patients

AU - Lundy, Jonathan B.

AU - Hetz, Katherine

AU - Chung, Kevin K.

AU - Renz, Evan M.

AU - White, Christopher E.

AU - King, Booker T.

AU - Huzar, Todd

AU - Wolf, Steven

AU - Blackbourne, Lorne H.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Recent data demonstrate a possible mortality benefit in traumatically injured patients when given subcutaneous recombinant human erythropoietin (rhEPO). The purpose of this report is to examine the effect of rhEPO on mortality and transfusion in burn patients.We conducted a review of burn patients (greater than 30% total body surface area, intensive care unit [ICU] days greater than 15) treated with 40,000u rhEPO over an 18-month period (January 2007 to July 2008). Matched historical controls were identified and a contemporaneous cohort of subjects not administered rhEPO was used for comparison (NrhEPO). Mortality, transfusions, ICU and hospital length of stay were assessed. A total of 105 patients were treated (25 rhEPO, 53 historical control group, 27 NrhEPO). Hospital transfusions (mean 13,704 ± mL vs 13,308 ± mL; P 5 0.42) and mortality (29.6 vs 32.0%; P = 0.64) were similar. NrhEPO required more blood transfusions (13,308 ± mL vs 6,827 ± mL; P = 0.004). No difference in mortality for the rhEPO and NrhEPO (32.0 vs 22.2%; P = 0.43) was found. Thromboembolic complications were similar in all three groups. No effect was seen for rhEPO treatment on mortality or blood transfusion requirements in the severely burned.

AB - Recent data demonstrate a possible mortality benefit in traumatically injured patients when given subcutaneous recombinant human erythropoietin (rhEPO). The purpose of this report is to examine the effect of rhEPO on mortality and transfusion in burn patients.We conducted a review of burn patients (greater than 30% total body surface area, intensive care unit [ICU] days greater than 15) treated with 40,000u rhEPO over an 18-month period (January 2007 to July 2008). Matched historical controls were identified and a contemporaneous cohort of subjects not administered rhEPO was used for comparison (NrhEPO). Mortality, transfusions, ICU and hospital length of stay were assessed. A total of 105 patients were treated (25 rhEPO, 53 historical control group, 27 NrhEPO). Hospital transfusions (mean 13,704 ± mL vs 13,308 ± mL; P 5 0.42) and mortality (29.6 vs 32.0%; P = 0.64) were similar. NrhEPO required more blood transfusions (13,308 ± mL vs 6,827 ± mL; P = 0.004). No difference in mortality for the rhEPO and NrhEPO (32.0 vs 22.2%; P = 0.43) was found. Thromboembolic complications were similar in all three groups. No effect was seen for rhEPO treatment on mortality or blood transfusion requirements in the severely burned.

UR - http://www.scopus.com/inward/record.url?scp=77957333506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957333506&partnerID=8YFLogxK

M3 - Article

VL - 76

SP - 951

EP - 956

JO - The American surgeon

JF - The American surgeon

SN - 0003-1348

IS - 9

ER -